Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment

, MT Newswires - 8:59 AM ET 3/31/2025 default

08:59 AM EDT, 03/31/2025 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said late Friday that the US Food and Drug Administration approved Qfitlia, a therapy designed to lower antithrombin, a protein inhibiting blood clotting.

The company said Qfitlia is approved for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients with hemophilia A or B.

Regulatory submissions have also been completed for Qfitlia in China and Brazil, it added.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.